

March 31, 2026



Avalon Quantum AI Announces Strategic Collaboration with Caylent, an Amazon Web Services Premier Tier Partner, to Advance its Catch-Up Product into a Fully Autonomous Agentic AI Video Platform

Collaboration Strengthens Development Roadmap and Supports Scalable Growth and Monetization

FREEHOLD, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- **Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ: ALBT)**, a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets, today announced that its subsidiary, Avalon Quantum AI LLC, has selected Caylent, Inc., a cloud-native services company and an Amazon Web Services (AWS) Premier Tier Consulting Partner, to support the development of this AWS-based initiative. This phase 2 development is expected to transition the Catch-Up software-as-a-service (SaaS) platform from a manually configured AI video production system into a fully autonomous, agentic AI-driven video platform.

The enhanced Catch-Up platform is intended to enable social media influencers, podcasters, and digital content creators to generate personalized video content across multiple platforms with minimal technical expertise.

The Catch-Up Agentic AI video platform is designed to automate the creation and distribution of short-form video and digital media content at scale. Leveraging advanced AI technologies, the platform is intended to enable rapid production of personalized, data-driven content, including video, audio, and digital storytelling formats, with minimal manual input. Designed for scalability and efficiency, Catch-Up was created to support brands, media companies, and enterprises in enhancing audience engagement, expanding digital reach, and optimizing content-driven monetization strategies across multiple channels.

"Partnering with Caylent represents an important step in advancing our AI platform capabilities and accelerating the development of our Catch-Up platform," stated Meng Li, Avalon's Interim Chief Executive Officer and Chief Operating Officer. "This collaboration supports phase 2 of our Catch-Up SaaS platform as we evolve into a fully autonomous, agentic AI solution with expanded capabilities and market reach. Working with a leading AWS Premier Tier provider strengthens our development roadmap and supports our ability to scale efficiently as we drive broader adoption and long-term monetization."

About Caylent

As an AWS Premier Tier Services Partner, Caylent is shaping the future where AI transforms industries responsibly and with excellence. We help companies build the solutions they need to succeed in today's market while enabling organizational evolution to thrive in a rapidly changing technology landscape. Our AI-enabled delivery methodology combined with our deep AWS experience turns our customers' ideas into impact, faster.

Caylent's achievements include being named AWS Migration Consulting Partner of the Year, GenAI Industry Solution Partner of the Year, and Industry Partner of the Year - Financial Services in 2024, Application Modernization Partner of the Year in 2023, AWS Innovation Partner of the Year in 2022, and AWS Rising Star Partner of the Year in 2021. Caylent's services include migrations, modernization, custom software development and generative AI. Learn more at <https://caylent.com/>

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: ALBT) is a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets. Through its wholly-owned subsidiary, Avalon Quantum AI LLC, the Company is advancing next-generation Agentic AI systems, including automated video generation, small business marketing, and workflow automation solutions. Avalon is also distributing the KetoAir™ breathalyzer device a non-invasive consumer breathalyzer that measures ketosis levels and is sold in North America, which is registered with the U.S. Food and Drug Administration as a Class I medical device.

For more information about Avalon, please visit www.avalon-globocare.com. Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release.

Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as "will", "anticipate", "estimate", "expect", "should", "may", and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company's commercialization, distribution and sales of its products and the product's ability to compete with other similar products. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the SEC, accessible through the SEC's website (<http://www.sec.gov>), including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry

and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. The contents of any website referenced in this press release are not incorporated by reference herein.

Contact Information:

Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com



Source: Avalon GloboCare Corp.